

**REMARKS**

The examiner considers the claims to be drawn to four separate inventions or groups of inventions and requires restriction to one of Groups I-IV for examination on the merits.

Applicants elect with traverse Group II, claims 7, 8, 17, 18 and new claim 19, drawn to a pharmaceutical composition comprising an anti-TNF antibody or fragment thereof. Traversal insofar as Groups II, III and IV are concerned is based on the fact that anti-TNF antibodies, TNF-RI and TNF-RII are all considered TNF sequestering antagonists and that such a genus of TNF sequestering antagonists were previously examined together by Examiner O'Hara in parent application 09/889,828, now issued as U.S. Patent 6,663,865. It is believed that, just as there was no serious burden on the examiner to examine the genus of TNF sequestering antagonists in parent application 09/889,828, there should be no serious burden to do the same in the present continuation application.

Withdrawal of the restriction requirement insofar as Groups II-IV are concerned and examination of Groups II-IV together in the instant application are therefore respectfully requested.

Favorable consideration and allowance are therefore respectfully solicited.

Appln. No. 10/666,335  
Amd. dated May 31, 2006  
Reply to Office Action of May 8, 2006

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C.  
Attorneys for Applicant(s)

By /ACY/  
Allen C. Yun  
Registration No. 37,971

ACY:pp  
Telephone No.: (202) 628-5197  
Facsimile No.: (202) 737-3528  
G:\BN\S\Ser1\Borrelli2A\pto\2006-05-31amendment.doc